AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
Are Biotech Companies Facing Unforeseen Hurdles?
February 01, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights,Percheron Therapeutics (ASX:PER) discontinues its lead candidate following a DMD trial setback.,Immutep (ASX:IMM) continues multiple clinical programs amid valuation challenges.,Impedimed (ASX:IPD) and Micro-X (ASX:MX1) secure funds to sup...
Is the Health Sciences Sector Experiencing Significant Change?
February 01, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights,Sigma Healthcare (ASX:SIG) to combine operations with Chemist Warehouse in a major industry realignment.,Biome Australia (ASX:BIO) secures funding from the Food and Beverage Accelerator for its innovative probiotic strain research.,Cynata...
Is This Quiet Stock About to Shake Up the Market?
January 31, 2025 03:31 PM AEDT| By Team Kalkine MediaHighlights:,Alterity Therapeutics' stock surged by 260% in the past year.,Recent capital raise strengthens the company's financial position.,Investors should stay informed about possible risks linked to its outlook.,Alterity Therapeutics (ASX:ATH), a...
Prescient Therapeutics Gears Up for Transformative Year with New Leadership and Key FDA Clearance
January 31, 2025 01:38 PM AEDT| By Team Kalkine MediaHighlights:,New CEO James McDonnell,appointed,and FDA clearance received for PTX-100 Phase 2 clinical trial.,Successful IND application for PTX-100 Phase 2 trial in r/,rCTCL,, with immediate initiation.,Significant progress,in,CellPryme,and,OmniCAR,d...
Race Oncology (ASX:RAC) Advances RC220 Phase 1 Trial and Strengthens Leadership Team
January 31, 2025 12:12 PM AEDT| By Team Kalkine MediaHighlights,RC220 Phase 1 Trial Progress,:,Ethics and regulatory submissions completed, with first patient treatment,anticipated,in Q1 CY2025.,Leadership Expansion,:,Appointment of Dr Megan Baldwin as an independent non-executive director, along with...
Mesoblast (ASX:MSB) Advances Ryoncil Launch Following FDA Approval
January 31, 2025 11:12 AM AEDT| By Team Kalkine MediaHighlights:,Mesoblast (,ASX:MSB,) secures $260 million funding,for the commercial launch of,Ryoncil,in the US.,Ryoncil,gains FDA approval,, leading to a 54% surge in Mesoblast shares on December 19.,Ryoncil,targets,pediatric,complications,arising fro...
ResMed Shares Surge on Q2 Earnings Report, Revenue Jumps 10%
January 31, 2025 11:11 AM AEDT| By Team Kalkine MediaHighlights,Revenue Growth:,ResMed posted a 10% year-over-year revenue increase to,$1.3 billion,, exceeding market expectations.,Profit Surge:,Operating income jumped,52%,to,$417.2 million,, while non-GAAP net income rose,29%,to,$358.3 million,.,Posit...
How Are Paradigm Biopharmaceuticals' Strategic Initiatives Shaping Its Future?
January 31, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights:,Paradigm Biopharmaceuticals introduces a loyalty and piggyback options offer, aimed at raising over $110 million.,Shareholders can benefit from additional shares through the company's loyalty options program.,The company prepares to launc...
What’s Driving the Surge in ASX Health Stocks?
January 31, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights,The S&P/ASX 200 Health Care Index rose by 3.3% last week, outperforming the general market's 1.9% increase.,Microba’s quarterly sales surged, while Mach7 Technologies initiated a $5 million share buyback.,Aroa Biosurgery faced a setback fo...
Steady Growth at Medical Developments International Limited (ASX:MVP) Supports Its Share Price
January 31, 2025 09:31 AM AEDT| By Team Kalkine MediaUnderstanding Medical Developments International's Current Valuation
Explore ASX Penny Stocks Highlighting Mayne Pharma Group and Two More
January 30, 2025 11:30 PM AEDT| By Team Kalkine MediaExploring ASX Penny Stocks Amid Market Dynamics
EZZ Life Science (ASX:EZZ) Lags, But Strong Financials Signal Potential
January 30, 2025 01:32 PM AEDT| By Team Kalkine MediaEZZ Life Science Holdings Limited (ASX:EZZ) Stock Has Been Underperforming Recently, Yet Financials Show Strength: Is It a Good Opportunity for Potential Shareholders?
ASX Quarterly Health Update: Bioxyne Sees 77% Revenue Increase, Radiopharm Debuts on Nasdaq
January 30, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights:,Bioxyne (ASX:BXN) achieves significant revenue growth with expanded product offerings.,Radiopharm Theranostics (ASX:RAD) makes progress with cancer therapies and strengthens US presence.,Tryptamine Therapeutics (ASX:TYP) advances in clini...
AdAlta strengthens leadership in the second quarter of fiscal year 2025 to enhance growth strategy.
January 30, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights,AdAlta expands leadership team with new board members and advisors to enhance growth plans.,First non-binding term sheet signed for East to West cellular therapy strategy in China.,Ongoing momentum in cellular immunotherapy and fibrosis tr...
Why Is This Low-Key Stock Suddenly Making Waves?
January 30, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights:,Blinklab Initiates FDA Study:,Blinklab (ASX:BB1) has launched an FDA registrational study for its Dx 1 platform, aimed at improving autism diagnosis, with final results expected by the end of CY25.,Mach7 Technologies Reports Growth:,Mach7...
Bio-Gene Secures U.S. Defence Contracts for Innovative Insecticides, Shares Up 130%
January 29, 2025 01:33 PM AEDT| By Team Kalkine MediaHighlights,Major U.S. Defence Grants:,Bio-Gene Technology receives $3 million in contracts to develop its flagship insecticides.,Wearable Insecticide:,A $1.6 million grant will fund the development of Flavocide as a wearable product.,Bed Bug Solution...
Is Mesoblast Revolutionizing Stem-Cell Therapy for Inflammatory Diseases?
January 29, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights:,Mesoblast's Ryoncil therapy gains FDA approval for treating children with steroid-resistant Graft-versus-Host Disease (GvHD).,The company secured significant funding to expand its therapies for chronic heart disease and back pain.,Mesobla...
When Might Cyclopharm Limited (ASX:CYC) Become Profitable?
January 28, 2025 07:30 PM AEDT| By Team Kalkine MediaHighlights,Cyclopharm Limited is nearing breakeven,Average annual growth rate of 105% expected,No debt on balance sheet,Cyclopharm Limited (,ASX: CYC,), a prominent player in the medical equipment and radiopharmaceutical market across the Asia Pacifi...
Sigma Healthcare Shares Surge 10% Amid Strong Merger Partner Performance
January 28, 2025 02:16 PM AEDT| By Team Kalkine MediaHighlights,Sigma Healthcare shares rise 10.2% to AU$2.975, marking their highest level since January 14, as merger news boosts investor confidence.,Chemist Warehouse, SIG's merger partner, reports 13% growth in retail sales, with record 10.3% like-fo...
Arovella Therapeutics (ASX:ALA) Surges with 71% CAGR in Three Years, Rising 11% This Week
January 28, 2025 01:31 PM AEDT| By Team Kalkine MediaArovella Therapeutics (ASX:ALA) has provided its shareholders with an impressive compound annual growth rate (CAGR) of 71% over the past three years, with an 11% increase in the last week alone.
Advertise your brand on Kalkine Media